All our Publications on PubMed

Manoharan GB, Kopra K, Eskonen V, Härmä H, Abankwa D. High-throughput amenable fluorescence-assays to screen for calmodulin-inhibitors. Anal Biochem. 2019 Feb 27. pii: S0003-2697(18)31185-0. doi: 10.1016/j.ab.2019.02.015. [Epub ahead of print] PubMed PMID: 30825429.

Buehler U, Schulenburg K, Yurugi H, Šolman M, Abankwa D, Ulges A, Tenzer S, Bopp T, Thiede B, Zipp F, Rajalingam K. Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity. EMBO J. 2018 Aug 15;37(16). pii: e99429. doi: 10.15252/embj.201899429. Epub 2018 Jul 26. PubMed PMID: 30049713; PubMed Central PMCID: PMC6092617.

Sahlgren C, Meinander A, Zhang H, Cheng F, Preis M, Xu C, Salminen TA, Toivola D, Abankwa D, Rosling A, Karaman DŞ, Salo-Ahen OMH, Österbacka R, Eriksson JE, Willför S, Petre I, Peltonen J, Leino R, Johnson M, Rosenholm J, Sandler N. Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems. Adv Healthc Mater. 2017 Nov;6(21). doi: 10.1002/adhm.201700258. Epub 2017 Sep 11. Review. PubMed PMID: 28892296.

Posada IMD, Lectez B, Siddiqui FA, Oetken-Lindholm C, Sharma M, Abankwa D Opposite feedback to H-ras and K-ras4B downstream of SREBP1 Sci Rep. 2017 Aug 21;7(1):8944. doi: 10.1038/s41598-017-09387-8. PMID:28827765 Posada etal 2017, Sci Rep.

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner. Posada IMD, Lectez B, Sharma M, Oetken-Lindholm C, Yetukuri L, Zhou Y, Aittokallio T, Abankwa D. Oncotarget. 2017 Jul 4;8(27): 44550-44566. doi: 10.18632/oncotarget.17819. PMID:28562352 Posada et al 2017 Oncotarget

Najumudeen AK, Jaiswal A, Lectez B, Oetken-Lindholm C, Guzmán C, Siljamäki E, Posada IM, Lacey E, Aittokallio T, Abankwa D. Cancer stem cell drugs target K-ras signaling in a stemness context. Oncogene. 2016 Oct 6;35(40):5248-5262. doi: 10.1038/onc.2016.59. PMID: 26973241 Najumudeen et al 2016, Oncogene

Siljamäki E, Abankwa D. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling. Mol Cell Biol. 2016 Sep 26; 36(20):2612 –Siljamäki et al 2018, Mol.Cell. Biol.

Blaževitš O, Mideksa YG, Šolman M, Ligabue A, Ariotti N, Nakhaeizadeh H, Fansa EK, Papageorgiou AC, Wittinghofer A, Ahmadian MR, Abankwa D. Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering. Sci Rep. 2016 Apr 18;6:24165. doi: 10.1038/srep24165. PMID: 27087647 Blazevits et al 2016, Sci Rep.

Šolman M, Ligabue A, Blaževitš O, Jaiswal A, Zhou Y, Liang H, Lectez B, Kopra K, Guzmán C, Härmä H, Hancock JF, Aittokallio T, Abankwa D. Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation. Elife. 2015 Aug 14;4:e08905. Solman et al 2015, Elife

Guzmán C, Šolman M, Ligabue A, Blaževitš O, Andrade DM, Reymond L, Eggeling C, Abankwa D. The efficacy of Raf kinase recruitment to the GTPase H-ras depends on H-ras membrane conformer-specific nanoclustering. J Biol Chem. 2014 Apr 4; 289(14): 9519-33.  Guzman et al 2014, J Biol Chem